Literature DB >> 17634453

Scanning the genome for coronary risk.

Anthony Rosenzweig.   

Abstract

Mesh：

Year:  2007        PMID： 17634453     DOI： 10.1056/NEJMe078121

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Cell therapies and regenerative medicine.

Authors:  Hubert E Blum
Journal:  Hepatol Int       Date:  2014-01-19       Impact factor: 6.047

2.  Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.

Authors:  Tamali Bhattacharyya; Stephen J Nicholls; Eric J Topol; Renliang Zhang; Xia Yang; David Schmitt; Xiaoming Fu; Mingyuan Shao; Danielle M Brennan; Stephen G Ellis; Marie-Luise Brennan; Hooman Allayee; Aldons J Lusis; Stanley L Hazen
Journal:  JAMA       Date:  2008-03-19       Impact factor: 56.272

3.  Individualized medicine 2010.

Authors:  Hubert E Blum
Journal:  J Cell Mol Med       Date:  2010-09       Impact factor: 5.310

4.  Relationship between Long Noncoding RNA H19 Polymorphisms and Risk of Coronary Artery Disease in a Chinese Population: A Case-Control Study.

Authors:  Wei-Na Hu; Han-Xi Ding; Qian Xu; Xue-Ying Zhang; Da-Tong Yang; Yuan-Zhe Jin
Journal:  Dis Markers       Date:  2020-05-10       Impact factor: 3.434

5.  Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study.

Authors:  Rakesh S Birjmohun; Menno Vergeer; Erik S G Stroes; Manjinder S Sandhu; Sally L Ricketts; Michael W Tanck; Nicholas J Wareham; J Wouter Jukema; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Journal:  PLoS One       Date:  2009-08-27       Impact factor: 3.240

6.  Relationship between long non-coding RNA polymorphism and the risk of coronary artery disease: A protocol for systematic review and meta-analysis.

Authors:  Bolin Wang; Zhihui Su; Lijun Wan; Tao He
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.